{
    "2018-03-12": [
        [
            {
                "time": "2018-03-12",
                "original_text": "恒瑞医药(600276.SH)：“缬沙坦氨氯地平片(I)”获得药品注册证书",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "药品注册证书",
                        "缬沙坦氨氯地平片"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-12",
                "original_text": "乐普医疗:君实生物PD-1单抗新药申请获受理,乐普肿瘤及心血管外延布局持续推进",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "君实生物",
                        "PD-1单抗",
                        "新药申请"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-12",
                "original_text": "北上资金调仓换股，重新看好茅台等新宠",
                "features": {
                    "keywords": [
                        "北上资金",
                        "调仓换股",
                        "茅台"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-12",
                "original_text": "医改联动药企创新加速，优质龙头迎机遇",
                "features": {
                    "keywords": [
                        "医改",
                        "药企创新",
                        "优质龙头"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-12",
                "original_text": "研发投入约1535万元，恒瑞4类化药获批",
                "features": {
                    "keywords": [
                        "研发投入",
                        "恒瑞",
                        "化药获批"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}